Summary
Cyclosporine has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Gout would be drug repurposing rather than first-in-human development. This does not mean it is approved for Gout. No registered clinical trial in this database tests Cyclosporine specifically in Gout. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study. The literature layer holds 7 publications for this pair: 1 Cochrane review, 1 randomised controlled trial publication and 5 clinical trial publications. Publication years run from 1988 to 2021. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Gout ranks 186 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Acute flares self-resolve in 7-14 days without treatment; but urate crystal deposition continues; only 10-15% achieve serum urate <360 µmol/L spontaneously without ULT; progressive tophus formation and joint damage in untreated patients.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 38.0 (trials 0.0, literature 18.0, tier 15, approved bonus 5.0) |
| Registered trials | 0 total: 0 recruiting, 0 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 7 (5 clinical trial publications, 1 Cochrane review, 1 randomised controlled trial publication) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | inhibitor |
| Data sources | DGIdb |
| Linked via biomarker / target | ABCG2 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
No registered trial links Cyclosporine to Gout in the current OSMF trial extract.
Published literature
- Cochrane review Prevalence of Musculoskeletal Manifestations in Adult Kidney Transplant's Recipients: A Systematic ReviewHassan AB, Ghalib KW, Jahrami HA et al. · Medicina (Kaunas, Lithuania) · 2021 · PMID 34071098
- Clinical trial publication Effect of cyclosporine on the pharmacokinetics of colchicine in healthy subjectsWason S, Digiacinto JL, Davis MW · Postgraduate medicine · 2012 · PMID 22913907
- Clinical trial publication Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitorsTerkeltaub RA, Furst DE, Digiacinto JL et al. · Arthritis and rheumatism · 2011 · PMID 21480191
- Clinical trial publication Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathyBakker RC, Hollander AA, Mallat MJ et al. · Kidney international · 2003 · PMID 12911553
- Clinical trial publication Hyperuricemia and gout in renal transplant recipientsAbdelrahman M, Rafi A, Ghacha R et al. · Renal failure · 2002 · PMID 12166703
- Clinical trial publication Natural history and etiology of hyperuricemia following pediatric renal transplantationEdvardsson VO, Kaiser BA, Polinsky MS et al. · Pediatric nephrology (Berlin, Germany) · 1995 · PMID 7742224
- Randomized controlled trial Hyperuricemia after renal transplantationGores PF, Fryd DS, Sutherland DE et al. · American journal of surgery · 1988 · PMID 3056057
Mechanism and notes
Recorded mechanism or class: inhibitor.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ABCG2. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Cyclosporine approved for Gout?
Cyclosporine has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Gout would be drug repurposing rather than first-in-human development. This does not mean it is approved for Gout. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Cyclosporine in clinical trials for Gout?
No registered clinical trial in this database tests Cyclosporine specifically in Gout. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study.
What does the evidence show for Cyclosporine in Gout?
Synthesis-level literature links Cyclosporine to Gout, but no registered trial in this database tests the pair, so the evidence is observational, pooled from other indications, or pre-dates registry practice. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target ABCG2. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.